Literature DB >> 33479657

Synthesis, evaluation and molecular modelling of piceatannol analogues as arginase inhibitors.

J Muller1, B Cardey2, A Zedet1, C Desingle1, M Grzybowski3, P Pomper3, S Foley2, D Harakat4, C Ramseyer2, C Girard1, M Pudlo1.   

Abstract

Arginase is involved in a wide range of pathologies including cardiovascular diseases and infectious diseases whilst it is also a promising target to improve cancer immunotherapy. To date, only a limited number of inhibitors of arginase have been reported. Natural polyphenols, among them piceatannol, are moderate inhibitors of arginase. Herein, we report our efforts to investigate catechol binding by quantum chemistry and generate analogues of piceatannol. In this work, we synthesized a novel series of amino-polyphenols which were then evaluated as arginase inhibitors. Their structure-activity relationships were elucidated by deep quantum chemistry modelling. 4-((3,4-Dihydroxybenzyl)amino)benzene-1,2-diol 3t displays a mixed inhibition activity on bovine and human arginase I with IC50 (K i) values of 76 (82) μM and 89 μM, respectively. This journal is © The Royal Society of Chemistry 2020.

Entities:  

Year:  2020        PMID: 33479657      PMCID: PMC7593889          DOI: 10.1039/d0md00011f

Source DB:  PubMed          Journal:  RSC Med Chem        ISSN: 2632-8682


  36 in total

1.  Rational design of novel irreversible inhibitors for human arginase.

Authors:  Xuefeng Guo; Yiming Chen; Christopher T Seto
Journal:  Bioorg Med Chem       Date:  2018-06-14       Impact factor: 3.641

Review 2.  Phenolic Compounds as Arginase Inhibitors: New Insights Regarding Endothelial Dysfunction Treatment.

Authors:  Bruno Rodrigo Minozzo; Daniel Fernandes; Flávio Luís Beltrame
Journal:  Planta Med       Date:  2018-01-17       Impact factor: 3.352

3.  Piceatannol-3'-O-beta-D-glucopyranoside as an active component of rhubarb activates endothelial nitric oxide synthase through inhibition of arginase activity.

Authors:  Ainieng Woo; Byungsun Min; Sungwoo Ryoo
Journal:  Exp Mol Med       Date:  2010-07-31       Impact factor: 8.718

4.  A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors.

Authors:  A Cornish-Bowden
Journal:  Biochem J       Date:  1974-01       Impact factor: 3.857

5.  Synthesis of quaternary α-amino acid-based arginase inhibitors via the Ugi reaction.

Authors:  Adam Golebiowski; Darren Whitehouse; R Paul Beckett; Michael Van Zandt; Min Koo Ji; Todd R Ryder; Erik Jagdmann; Monica Andreoli; Yung Lee; Ryan Sheeler; Bruce Conway; Jacek Olczak; Marzena Mazur; Wojciech Czestkowski; Wieslawa Piotrowska; Alexandra Cousido-Siah; Francesc X Ruiz; Andre Mitschler; Alberto Podjarny; Hagen Schroeter
Journal:  Bioorg Med Chem Lett       Date:  2013-07-08       Impact factor: 2.823

Review 6.  Arginase Inhibitors: A Rational Approach Over One Century.

Authors:  Marc Pudlo; Céline Demougeot; Corine Girard-Thernier
Journal:  Med Res Rev       Date:  2016-11-15       Impact factor: 12.944

7.  Inhibition of human arginase I by substrate and product analogues.

Authors:  Luigi Di Costanzo; Monica Ilies; Katherine J Thorn; David W Christianson
Journal:  Arch Biochem Biophys       Date:  2010-02-12       Impact factor: 4.013

8.  Arginase inhibition by piceatannol-3'-O-β-D-glucopyranoside improves endothelial dysfunction via activation of endothelial nitric oxide synthase in ApoE-null mice fed a high-cholesterol diet.

Authors:  Ainieng Woo; Woosung Shin; To Dao Cuong; Byungsun Min; Jeong Hyung Lee; Byung Hwa Jeon; Sungwoo Ryoo
Journal:  Int J Mol Med       Date:  2013-01-30       Impact factor: 4.101

9.  Identification of an Arginase II Inhibitor via RapidFire Mass Spectrometry Combined with Hydrophilic Interaction Chromatography.

Authors:  Wataru Asano; Yu Takahashi; Motoaki Kawano; Yoshiji Hantani
Journal:  SLAS Discov       Date:  2018-12-07       Impact factor: 3.341

10.  Arginase expression modulates nitric oxide production in Leishmania (Leishmania) amazonensis.

Authors:  Stephanie Maia Acuña; Juliana Ide Aoki; Maria Fernanda Laranjeira-Silva; Ricardo Andrade Zampieri; Juliane Cristina Ribeiro Fernandes; Sandra Marcia Muxel; Lucile Maria Floeter-Winter
Journal:  PLoS One       Date:  2017-11-14       Impact factor: 3.240

View more
  2 in total

1.  Virtual Screening for FDA-Approved Drugs That Selectively Inhibit Arginase Type 1 and 2.

Authors:  Trishna Saha Detroja; Abraham O Samson
Journal:  Molecules       Date:  2022-08-12       Impact factor: 4.927

2.  OATD-02 Validates the Benefits of Pharmacological Inhibition of Arginase 1 and 2 in Cancer.

Authors:  Marcin Mikołaj Grzybowski; Paulina Seweryna Stańczak; Paulina Pomper; Roman Błaszczyk; Bartłomiej Borek; Anna Gzik; Julita Nowicka; Karol Jędrzejczak; Joanna Brzezińska; Tomasz Rejczak; Nazan Cemre Güner-Chalimoniuk; Agnieszka Kikulska; Michał Mlącki; Jolanta Pęczkowicz-Szyszka; Jacek Olczak; Adam Gołębiowski; Karolina Dzwonek; Paweł Dobrzański; Zbigniew Zasłona
Journal:  Cancers (Basel)       Date:  2022-08-17       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.